Drug delivery system
The subject invention provides a drug delivery system comprising at least one compartment consisting of (i) a drug-loaded thermoplastic polymer core, (ii) a drug-loaded thermoplastic polymer intermediate layer and (iii) a non-medicated thermoplastic polymer skin covering the intermediate layer, wherein said intermediate layer is loaded with (a) crystals of a first pharmaceutically active compound and with (b) a second pharmaceutically active compound in dissolved form and wherein said core is loaded with said second compound in dissolved form.
1. A vaginal ring comprising (i) a drug-loaded ethylene-vinylacetate copolymer core, (ii) a drug-loaded ethylene-vinylacetate copolymer intermediate layer and (iii) a non-medicated ethylene-vinylacetate copolymer skin covering the intermediate layer, wherein said intermediate layer is loaded with (a) crystals of a first pharmaceutically active compound, wherein the first pharmaceutically active compound is a steroid and with (b) a second pharmaceutically active compound in dissolved form and wherein said core is loaded with the second pharmaceutically active compound such that the pharmaceutically active compound in the core is present only in dissolved form and wherein the second pharmaceutically active compound is etonogestrel.
2. The vaginal ring according to claim 1 which is physically stable at about 18-30° C.
3. The vaginal ring according to claim 1 wherein etonogestrel in the core is present in the same concentration as in the intermediate layer.
4. The vaginal ring according to claim 3 wherein etonogestrel is present in the intermediate layer at about 6-80% by weight.
5. A method of contraception which comprises the steps of (i) positioning the vaginal ring of claim 1 within the female vaginal tract and (ii) retaining the system within the vaginal tract for at least about 21 days.
6. The vaginal ring according to claim 1 , wherein the core and the intermediate layer comprise a different grade of ethylene-vinylacetate copolymer.